妇科恶性肿瘤患者外周血淋巴细胞中的腺苷脱氨酶活性
Adenosine deaminase activity in peripheral lymphocytes of patients with gynaecologic malignancies.
作者信息
Specchia G, Pavone V, Maggio F, Lojudice L, Iacobazzi A, De Tullio L, Cagnazzo G, Liso V
出版信息
Boll Ist Sieroter Milan. 1985;64(5):404-7.
Peripheral lymphocyte adenosine deaminase (ADA) activity was assessed in a group of 31 patients with gynaecologic malignancies (19 with carcinoma of the portio, 7 with endometrial adenocarcinoma, 3 with ovarian cancer, 1 with adenocarcinoma of the cervix, 1 with liposarcoma myxoide). 30 female subjects, aged 30 to 70 years, were studied as the control group. Lymphocyte ADA activity in the 31 patients ranged from 0 to 7 U/10(7) cells with a mean of 2.3 U/10(7) cells (normal values: range 2-5 U/10(7) cells; mean 2.8 U/10(7) cells). In cases where the enzyme was absent or far below the controls, a faster evolution of the disease was observed. We would point out that lymphocyte ADA activity in the patients under investigations shows a broad range of variability. Our preliminary observations would suggest that lymphocyte ADA assessment in a larger series of cancer patients may add further prognostic informations.
对一组31例妇科恶性肿瘤患者（19例宫颈部癌、7例子宫内膜腺癌、3例卵巢癌、1例宫颈腺癌、1例黏液样脂肪肉瘤）的外周淋巴细胞腺苷脱氨酶（ADA）活性进行了评估。选取30名年龄在30至70岁的女性作为对照组。31例患者的淋巴细胞ADA活性范围为0至7 U/10⁷细胞，平均为2.3 U/10⁷细胞（正常值范围：2至5 U/10⁷细胞；平均2.8 U/10⁷细胞）。在该酶缺失或远低于对照组的病例中，观察到疾病进展更快。我们要指出的是，所研究患者的淋巴细胞ADA活性显示出广泛的变异性。我们的初步观察结果表明，对更多癌症患者进行淋巴细胞ADA评估可能会提供更多预后信息。
Zotero 插件